4.5 Review

Immune response to vaccine adjuvants during the first year of life

Journal

VACCINE
Volume 31, Issue 21, Pages 2500-2505

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.10.016

Keywords

Adjuvants; Innate immunity; Vaccines; Newborn; Infant; Immunization

Funding

  1. Burroughs Wellcome Fund
  2. Michael Smith Foundation
  3. Canadian Institutes of Health Research
  4. US National Institute of Allergy and Infectious Diseases
  5. GlaxoSmithKline
  6. Merck
  7. Advaxis
  8. Allergen NCE
  9. government of the Walloon Region
  10. GlaxoSmithKline Biologicals
  11. Fonds de la Recherche Scientifique (FRS-FNRS, Belgium)
  12. U.S. National Institutes of Health (NIH) [R01AI100135-01]
  13. Bill & Melinda Gates Foundation [OPPGH5284, OPP1035192]
  14. VentiRx Pharmaceuticals
  15. FNRS
  16. Bill and Melinda Gates Foundation [OPP1035192, OPPGH5284] Funding Source: Bill and Melinda Gates Foundation

Ask authors/readers for more resources

Subunit vaccine formulations often include adjuvants that primarily stimulate innate immune cells. While young infants represent the major target population for vaccination, effective immunization in this age group remains a challenge. Many parameters of innate immune responses differ quantitatively and qualitatively from newborns to infants and adults, revealing a highly regulated developmental program. Herein, we discuss the potential implications of innate immune ontogeny for the activity of adjuvants contained in licensed infant vaccines, as well as future directions for rational design of adjuvanted vaccines for this age group. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available